<code id='B5543DB876'></code><style id='B5543DB876'></style>
    • <acronym id='B5543DB876'></acronym>
      <center id='B5543DB876'><center id='B5543DB876'><tfoot id='B5543DB876'></tfoot></center><abbr id='B5543DB876'><dir id='B5543DB876'><tfoot id='B5543DB876'></tfoot><noframes id='B5543DB876'>

    • <optgroup id='B5543DB876'><strike id='B5543DB876'><sup id='B5543DB876'></sup></strike><code id='B5543DB876'></code></optgroup>
        1. <b id='B5543DB876'><label id='B5543DB876'><select id='B5543DB876'><dt id='B5543DB876'><span id='B5543DB876'></span></dt></select></label></b><u id='B5543DB876'></u>
          <i id='B5543DB876'><strike id='B5543DB876'><tt id='B5543DB876'><pre id='B5543DB876'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:leisure time    Page View:1
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In